{"id":"NCT00783718","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis","officialTitle":"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2011-12","completion":"2012-03","firstPosted":"2008-11-03","resultsPosted":"2014-07-18","lastUpdate":"2014-07-18"},"enrollment":895,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"vedolizumab","otherNames":["Entyvio","MLN0002","MLN02","LDP-02"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Vedolizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.","primaryOutcome":{"measure":"Induction Phase: Percentage of Participants With a Clinical Response at Week 6","timeFrame":"Baseline and Week 6","effectByArm":[{"arm":"Placebo","deltaMin":25.5,"sd":null},{"arm":"DB Vedolizumab","deltaMin":47.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":105,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":["23964932","35934286","33200296","32635680","32606883","32062041","30365009","30285104","30203005","29857145","27802155","27639327","26893500","25996351"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":149},"commonTop":["Headache","Nasopharyngitis","Colitis ulcerative","Arthralgia","Upper respiratory tract infection"]}}